A study claims Celebrex should not receive preferential treatment over Vioxx.
|
A new study concludes that Celebrex is no safer than similar drugs that have been pulled from the market.
|
A new study suggests that a chemical relation to Pfizer’s COX-2 inhibitor could become a treatment for multiple myeloma.
|
Merck’s market cap tumbles $5.17 billion after a jury awards $253 million in the first case focused on the painkiller.
|
Remicade takes on Enbrel; legislation for child drug research; Pfizer’s Celebrex gets pickings from Bextra; new South African AIDS figures.
|
Merck board replaces longtime CEO Ray Gilmartin with Richard Clark, who’s been with Merck since 1972.
|
A study finds 15 medical treatments linked to serious reactions, including 170 deaths.
|
Guidant OKs J&J acquisition; Merck takes an offensive stance in Vioxx litigation; device developed for head-bangers; Abiomed announces acquisition plans.
|
Merck sees first-quarter income fall 15 percent while Schering-Plough sees light at the end of the tunnel with stronger results. Both stocks rise.
|
Scios’ Natrecor and Novartis’ Trileptal are the latest to raise red flags over safety concerns.
|
Pfizer says it disagrees with regulators, but will withdraw Bextra and re-label Celebrex on concerns about COX-2 drugs.
|